Semaglutides: weighing up the risks
-
Podcast 2025年4月22日 2025年4月22日
-
北美洲, 英国和欧洲
-
Regulatory movement
-
保险和再保险
The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.
Partner Neil Beresford is joined by:
- Rosehana Amin, Partner, London
- Kirsten Soto, Senior Associate, Los Angeles
- Richard Manstoff, Senior Associate, London
Together they explore the potential risks and lawsuits surrounding Semaglutides, including their side effects and possible implications for insurers.
结束
